Concert Pharma (CNCE) Tops Q1 EPS by 8c

Concert Pharma (NASDAQ: CNCE) reported Q1 EPS of ($0.70), $0.08 better than the analyst estimate of ($0.78).

“We are continuing to move forward the development of our two clinical drug candidates. Following discussions with the FDA at an End-of-Phase 2 meeting in March, CTP-543 is on the cusp of initiating its Phase 3 clinical program for the treatment of moderate-to-severe alopecia areata later this year. In addition, despite challenges in enrollment due to COVID-19, we have been successful in keeping our Phase 2 trial of CTP-692 up and running and currently expect to complete enrollment by year-end 2020,” stated Roger Tung, Ph.D., President and Chief Executive Officer of Concert Pharmaceuticals. “We are closely monitoring our clinical programs and are actively working with all of the stakeholders involved so that we can attempt to minimize the impact of COVID-19.”

For earnings history and earnings-related data on Concert Pharma (CNCE) click here.

You May Also Be Interested In

• Vivos Therapeutics posts 35% revenue gain but widens net loss
• Hydrofarm Holdings Group, Inc. (HYFM) Misses Q2 EPS by 134c
• Evogene chairman to address dissident shareholders on results call